Pablo Rojo-Conejo
Madrid, MD, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 124 publications
An urgent opportunity to ensure children's access to oral post-exposure prophylaxis trials for Bundibugyo virus disease.
Journal: The Lancet. Child & adolescent health
Published: August 20, 2026
Barriers and facilitators to adherence of infants living with HIV in sub-Saharan Africa in an era of wide access to ART: a mixed-methods study.
Journal: AIDS and behavior
Published: July 10, 2026
Invasive mold infections in the pediatric setting: current status and new developments.
Journal: Expert review of anti-infective therapy
Published: May 11, 2026
HIV broadly neutralizing antibodies for children: implementation barriers in low-income settings.
Journal: Current opinion in HIV and AIDS
Published: May 07, 2026
Broadly neutralizing antibodies for treatment of HIV in children in the Global South: rationale and challenges.
Journal: Frontiers in pediatrics
Published: March 18, 2026
Pharmacokinetics of abacavir and lamivudine in infants living with HIV with and without rifampicin co-treatment.
Journal: The Journal of antimicrobial chemotherapy
Published: February 19, 2026
Safety and Pharmacokinetics of the RSV Fusion Inhibitor Sisunatovir Across Two Early-phase Studies in Infants and Children With RSV Lower Respiratory Tract Infection.
Journal: The Pediatric infectious disease journal
Published: February 12, 2026
Dolutegravir as First- or Second-line Treatment for Children With HIV: 240-Week Follow-up of the ODYSSEY Randomized Trial.
Journal: Open forum infectious diseases
Published: January 26, 2026
Pharmacokinetics and pharmacodynamics of valganciclovir in infants with severe HIV-associated pneumonia in Africa: a sub-study of the EMPIRICAL randomised controlled trial.
Journal: EClinicalMedicine
Published: January 08, 2026
SHIELD study: a multicenter, open-label, single-arm trial to evaluate the safety, pharmacokinetics and antiviral activity of fostemsavir in combination with optimized background therapy (OBT) in children and adolescents with HIV who are failing their current combination antiretroviral therapy (cART) and have dual- or triple-class antiretroviral (ARV) resistance.
Journal: BMC infectious diseases
Published: January 07, 2026
Empirical treatment with valganciclovir in infants living with HIV and hospitalised with severe pneumonia in Africa: a multicentre, open-label, factorial, randomised, controlled, superiority trial.
Journal: Lancet (London, England)
Published: December 11, 2025
Predictors of Treatment Failure in Children With HIV Starting First-line Antiretroviral Therapy in the ODYSSEY Trial.
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: October 16, 2025
Last Updated: 09/26/2026